Company intelligence / Profile preview

Rachael McLean

McLean, Virginia, United Statesrachaelmclean.com ↗

Ownership: Private
Development stage: Other

Overview

Zephyr AI develops explainable artificial intelligence tools to advance precision medicine. The company has presented novel composite biomarkers effective in predicting sensitivity to PARP inhibition in late-line cancer patients and recently raised $111 million in Series A financing.

Therapeutic areas: Oncology
Modalities: Artificial intelligence platform
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Rachael McLean.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rachael McLean.

Explore the full profile